{
 "id": "osteoporosis",
 "name": "Osteoporosis",
 "aliases": [],
 "acronyms": [],
 "bodySystem": "endocrine",
 "parent": null,
 "children": [],
 "edition": "2026-11",
 "merkleRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "builtFrom": "program.status and program.eligibility facts, grouped by the condition registry",
 "counts": {
  "open": 0,
  "limited": 0,
  "waitlist": 0,
  "closed": 1
 },
 "funds": [
  {
   "fund": "Osteoporosis",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 2500,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  }
 ],
 "drugsWhoseLabelNamesThisCondition": [
  {
   "ingredient": "Estrogens, Conjugated",
   "pages": [
    {
     "brand": "Premarin",
     "url": "https://omnirx.org/medicines/premarin"
    }
   ],
   "labelSentence": "Prevention of Postmenopausal Osteoporosis ( 1.",
   "labelContext": "risk-reduction",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22258e1602-a3cf-4ccc-ca80-73dbbfb812ff%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Pfizer RxPathways (Pfizer Patient Assistance Program)",
     "url": "https://omnirx.org/assistance/pfizer-rxpathways",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "products remaining within Pfizer PAP as of January 1, 2026",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Romosozumab-Aqqg",
   "pages": [
    {
     "brand": "Evenity",
     "url": "https://omnirx.org/medicines/evenity"
    }
   ],
   "labelSentence": "EVENITY is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture;",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22471baba2-7154-4488-9891-0db2f46791e7%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Amgen Safety Net Foundation",
     "url": "https://www.amgensafetynetfoundation.com/eligibility.html",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "Eligibility page medication selector (tile titles)",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Teriparatide",
   "pages": [
    {
     "brand": "Forteo",
     "url": "https://omnirx.org/medicines/forteo"
    },
    {
     "brand": "Teriparatide",
     "url": "https://omnirx.org/medicines/teriparatide"
    }
   ],
   "labelSentence": "For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available ...",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%229d3f65e2-e8f0-4d33-b79e-989013dd3ca3%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Lilly Cares Foundation Patient Assistance Program",
     "url": "https://omnirx.org/assistance/lilly-cares",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Available Medications: list of all products",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Abaloparatide",
   "pages": [
    {
     "brand": "Tymlos",
     "url": "https://omnirx.org/medicines/tymlos"
    }
   ],
   "labelSentence": "Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22712143d9-e21e-4013-bb3b-3426a21060a8%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Denosumab",
   "pages": [
    {
     "brand": "Prolia",
     "url": "https://omnirx.org/medicines/prolia"
    }
   ],
   "labelSentence": "... of postmenopausal women with osteoporosis at high risk for fracture ( 1.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2239a0a789-778f-4695-b3a9-61643e6396cd%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  }
 ],
 "fundsForRelatedCosts": [],
 "note": "Each status is what the fund page said on readOn. It is not an eligibility determination. We hold only the organizations we read; no fund here does not mean no fund exists.",
 "licence": "CC BY 4.0 for the OmniRx compilation"
}